How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Anilazine Market
- By Formulation Type: Wettable Powder (WP), Granules (GR), Suspension Concentrate (SC), Emulsifiable Concentrate (EC)
- By Application: Fungicide for Cereals, Fungicide for Vegetables, Fungicide for Fruits, Fungicide for Ornamentals
- By Mode of Application: Foliar Spray, Seed Treatment, Soil Treatment
- By Crop Type: Cereals & Grains, Fruits & Vegetables, Oilseeds & Pulses, Turf & Ornamentals
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Wettable Powder (WP) leads By Formulation Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 258 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.161 →
- 11 Company Profiles 10 players: SWOT & benchmarking p.169 →
Full report · locked preview
Everything inside the Anilazine Market report
A complete, evidence-based study - 11 chapters and 108 sections covering market size, segmentation across 4 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Formulation Type 4
Application 4
Mode of Application 3
Crop Type 4
Companies profiled
Nippon Soda Co. Ltd.
Jiangsu Yangnong Chemical Group Co. Ltd.
Shandong Rainbow Chemical Co. Ltd.
Hebei Veyong Pharmaceutical Co. Ltd.
Jiangsu Lanfeng Bio-Chem Co. Ltd.
Hebei Jiheng Chemical Co. Ltd.
Shandong Jiejing Group Corporation
Nanjing Red Sun Co. Ltd.
Hebei Huaxing Chemical Co. Ltd.
Zhejiang Xinan Chemical Industrial Group Co. Ltd.
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Nippon Soda Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Jiangsu Yangnong Chemical Group Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Shandong Rainbow Chemical Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Hebei Veyong Pharmaceutical Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Jiangsu Lanfeng Bio-Chem Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Hebei Jiheng Chemical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Shandong Jiejing Group Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Nanjing Red Sun Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Hebei Huaxing Chemical Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Zhejiang Xinan Chemical Industrial Group Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,494M by 2033 · 4.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Wettable Powder (WP)68.0
- Granules (GR)8.9
- Suspension Concentrate (SC)14.3
- Emulsifiable Concentrate (EC)8.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$837.9M → $1,243M · 5.1%
Europe$584.0M → $794.0M · 3.9%
Asia Pacific$533.2M → $824.9M · 5.6%
Latin America$330.1M → $497.5M · 5.3%
Middle East and Africa$253.9M → $379.2M · 5.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.022026
4.052027
4.052028
4.072029
4.082030
4.092031
4.092032
4.112033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Nippon Soda Co. Ltd.23.3
- Jiangsu Yangnong Chemical Group Co. Ltd.9.5
- Shandong Rainbow Chemical Co. Ltd.5.6
- Hebei Veyong Pharmaceutical Co. Ltd.11.0
- Jiangsu Lanfeng Bio-Chem Co. Ltd.11.0
- Hebei Jiheng Chemical Co. Ltd.11.7
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Formulation Type34.8%
Application22.7%
Mode of Application13.7%
Crop Type28.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.3
- Europe21.2
- Asia Pacific22.1
- Latin America13.3
- Middle East and Africa10.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Nippon Soda Co. Ltd. | 82 | 83 | 93 | 93 | 80 | 81 | 85 |
| Jiangsu Yangnong Chemical Group Co. Ltd. | 86 | 74 | 78 | 72 | 86 | 75 | 79 |
| Shandong Rainbow Chemical Co. Ltd. | 73 | 85 | 86 | 74 | 83 | 68 | 78 |
| Hebei Veyong Pharmaceutical Co. Ltd. | 80 | 81 | 81 | 68 | 70 | 72 | 75 |
| Jiangsu Lanfeng Bio-Chem Co. Ltd. | 51 | 59 | 53 | 51 | 64 | 60 | 56 |
| Hebei Jiheng Chemical Co. Ltd. | 61 | 61 | 51 | 46 | 56 | 56 | 55 |
| Shandong Jiejing Group Corporation | 47 | 65 | 54 | 64 | 50 | 42 | 54 |
| Nanjing Red Sun Co. Ltd. | 35 | 52 | 52 | 39 | 36 | 50 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Nippon Soda Co. Ltd.
- Jiangsu Yangnong Chemical Group Co. Ltd.
- Shandong Rainbow Chemical Co. Ltd.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Nippon Soda Co. Ltd. | ◐ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Jiangsu Yangnong Chemical Group Co. Ltd. | ◐ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Shandong Rainbow Chemical Co. Ltd. | ✓ | ✓ | ◐ | ✓ | ✓ | − |
| Hebei Veyong Pharmaceutical Co. Ltd. | ✓ | ◐ | ◐ | ◐ | − | − |
| Jiangsu Lanfeng Bio-Chem Co. Ltd. | − | − | − | − | ◐ | ◐ |
| Hebei Jiheng Chemical Co. Ltd. | ◐ | ◐ | − | − | ◐ | − |
| Shandong Jiejing Group Corporation | − | ◐ | ◐ | ◐ | − | − |
| Nanjing Red Sun Co. Ltd. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Nippon Soda Co. Ltd.85
2Jiangsu Yangnong Chemical Group Co. Ltd.79
3Shandong Rainbow Chemical Co. Ltd.78
4Hebei Veyong Pharmaceutical Co. Ltd.75
5Jiangsu Lanfeng Bio-Chem Co. Ltd.56
6Hebei Jiheng Chemical Co. Ltd.55
7Shandong Jiejing Group Corporation54
8Nanjing Red Sun Co. Ltd.44
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Nippon Soda Co. Ltd.Jiangsu Yangnong Chemical Group Co. Ltd.Shandong Rainbow Chemical Co. Ltd.
Challenger1
Strong scale, closing on the leaders.
Hebei Veyong Pharmaceutical Co. Ltd.
Niche4
Specialists in a single segment or region.
Jiangsu Lanfeng Bio-Chem Co. Ltd.Hebei Jiheng Chemical Co. Ltd.Shandong Jiejing Group CorporationNanjing Red Sun Co. Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Formulation Type in North America, then scale across Anilazine Market — a $405M beachhead inside a $7.68B market.
Beachhead (SOM)$405Mobtainable near-term
Serviceable (SAM)$2.69Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Wettable Powder (WP)
Best fit — highest urgency & budget in Formulation Type.
Economic buyer79 fit
Granules (GR)
Strong fit — clear ROI and a fast path to value.
End user65 fit
Suspension Concentrate (SC)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Formulation Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Mode of Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel32%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Formulation Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Anilazine Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified25%
Evaluation13%
Closed-won5%
$18.7KCAC
$67KLTV
3.6:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Anilazine Market is a high-growth opportunity — $11.7B by 2033, compounding at 11.2%.
TAM · 2025$5.04Btoday
TAM · 2033$11.7Bforecast
CAGR11.2%2027–2033
Cumulative$71.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$11.7BTotal addressable market
SAM$4.60BServiceable available market
SOM$757MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.2% CAGR
Demand compounds through 2033, outpacing GDP across Formulation Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Formulation Type moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$11.7BLarge & growingTAM by 2033 at 11.2% CAGR
$4.60BServiceable nowreachable with today’s model
$757MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$9.16BBear7.3% CAGR
$11.7BBase11.2% CAGR
$15.0BBull14.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Anilazine Market — a $949M market by 2033. Plan: grow share from 7.4% to 12.9%.
Market size · 2033$949Mtotal addressable
Market CAGR7.4%2027–2033
Target share12.9%from 7.4% today
Revenue ambition$122Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.4% | 12.9% | Behind |
| Revenue | $75M | $122M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 37.3% | 38.0% | Behind |
| Customer retention | 85.3% | 93.7% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Formulation Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Formulation Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $16M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Formulation Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskAhead
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Anilazine Market conversation — a $4.45B market you can size, segment and defend in minutes.
Market size · 2033$4.45Btotal opportunity
Growth5.9%CAGR to 2033
Addressable buyers1,482+accounts in scope
Typical ROI5.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Formulation Type
Goal Grow share in Formulation Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.9×return on cost, year one
< 2 mopayback period
$85K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
Nippon Soda Co. Ltd.Jiangsu Yangnong Chemical Group Co. Ltd.Shandong Rainbow Chemical Co. Ltd.Hebei Veyong Pharmaceutical Co. Ltd.Jiangsu Lanfeng Bio-Chem Co. Ltd.Hebei Jiheng Chemical Co. Ltd.Shandong Jiejing Group CorporationNanjing Red Sun Co. Ltd.+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Anilazine Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Anilazine Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Aniline Formaldehyde Resin Market
Market size, share, segmentation and regional forecast.
$643M market · 2025 base year
View reportAniline Leather Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportAniline Modified Phenolic Molding Plastics Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportAnilox Roll Cleaning Machine Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportAnilox Roll Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportAnilox Roller Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportAnimal and Pet Food Flavors Market
Market size, share, segmentation and regional forecast.
$812M market · 2025 base year
View reportAnimal Animal Feed Enzymes Market
Market size, share, segmentation and regional forecast.
$985M market · 2025 base year
View reportAnimal Auto-Immune Disease Therapeutics Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportAnimal Bedding Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportAnimal biotics Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportAnimal Disinfectant Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.